NCI faces prospect of an 11% cut in FY25—another setback in a period of tight budgets and sliding paylines

HRSA redrafts 340B rebate pilot program after courts block the original version

After returning to the drawing board, the Health Resources and Services Administration has announced a second iteration of the 340B Rebate Model Pilot Program, after it withdrew the original pilot earlier this year.

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.

August 07, 2026

Vol.52 No.31

In Brief

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Dana-Farber Cancer Institute’s Department of Pathology, in collaboration with Brigham and Women’s Hospital, has received renewed funding for the Ruth L. Kirschstein NRSA Institutional Research Training Grant from the NCI, providing resources for pathology residents, clinical fellows, and PhD-trained scientists pursuing research careers in cancer pathology.

August 07, 2026

Vol.52 No.31

Cancer History Project

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock.

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.

July 31, 2026

Vol.52 No.30

Clinical Roundup

Moffitt-led team develops chemical approach to build safer precision medicines

Researchers at Moffitt Cancer Center have developed a chemical approach that could help make targeted cancer medicines safer and more precise.

July 31, 2026

Vol.52 No.30

NCI faces prospect of an 11% cut in FY25—another setback in a period of tight budgets and sliding paylines

YOU MAY BE INTERESTED IN

HRSA redrafts 340B rebate pilot program after courts block the original version

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Moffitt-led team develops chemical approach to build safer precision medicines

Renew today!

Subscriber content

Never miss an issue!

Login

NCI faces prospect of an 11% cut in FY25—another setback in a period of tight budgets and sliding paylines

YOU MAY BE INTERESTED IN

HRSA redrafts 340B rebate pilot program after courts block the original version

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”Chanock and Brawley reflect on their illustrious mentor

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Moffitt-led team develops chemical approach to build safer precision medicines

Never miss an issue!

Login

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor